VistaGen Therapeutics, Inc.
VTGN
$3.60
-$0.83-18.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -49.81% | -40.64% | -43.21% | -121.87% | -96.74% |
| Total Depreciation and Amortization | 17.83% | 11.92% | 12.93% | 12.59% | 12.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.26% | -30.41% | 58.14% | 92.90% | 66.44% |
| Change in Net Operating Assets | 378.12% | -230.11% | 38.21% | 180.17% | 391.08% |
| Cash from Operations | -26.39% | -73.39% | -44.05% | -116.56% | -75.86% |
| Capital Expenditure | 1.64% | -54.76% | -203.45% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.56% | 86.67% | -- | -- | -- |
| Cash from Investing | 98.79% | 85.59% | 1,917.24% | -1,218.75% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 534.09% | -- | -98.75% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 1,590.91% | 613.42% | -98.75% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 173.91% | -11.68% | -2.57% | -110.71% | -166.72% |